Cancer, a global health crisis, affects countless individuals worldwide, and many rely on surgery as a potential cure, hoping for the complete removal of tumors while sparing healthy tissues. Over the years, various advancements have been made to enhance surgical procedures, with visual imaging techniques, such as glowing dyes, proving invaluable.
However, a significant challenge arises with certain fluorescent probes, as they can inadvertently activate in healthy tissues due to endogenous enzymes, creating background fluorescence and complicating the identification of what needs to be removed. Conversely, cancer cells may remain unmarked, increasing the risk of recurrence.
Recognizing this shortcoming, our research group has developed an innovative approach to illuminate cancer cells within the body. In mouse trials, we introduced a specialized enzyme to tumors and utilized a fluorescence probe that only activates in the presence of this unique enzyme.
Ryosuke Kojima, an Associate Professor at the University of Tokyo's Laboratory of Chemical Biology and Molecular Imaging, explains: "Older probes often mistakenly light up healthy tissue, creating background noise. Our bioorthogonal dye probe, however, remains completely inactive unless it encounters its matching engineered enzyme. We achieved this through directed evolution, repeatedly mutating and selecting the enzyme until it could strongly activate the probe, making it suitable for use in living animals."
Kojima, alongside Professor Yasuterer Urano and their team, created a fluorescent probe that is resistant to activation by natural enzymes in the body, thus minimizing unwanted background glow. This probe was paired with a tailored reporter enzyme designed to activate it, ensuring fluorescence primarily occurs where the enzyme is delivered. When tested on mice with peritoneal cancer, the engineered enzyme successfully reached the tumors in the abdominal wall lining, and the probe illuminated as expected.
This system offers an unprecedented level of contrast, allowing the visualization of tiny, millimeter-sized tumor lesions with minimal background noise. In the short term, it can serve as a powerful research tool, and in the long term, it has the potential to aid surgeons in more complete tumor removal by clearly highlighting cancer cells. However, a significant hurdle remains: ensuring that the engineered enzyme does not trigger an unwanted immune response in patients.
The versatility of this system extends beyond peritoneal cancer. Many cancers present corresponding antigens, unique markers of tumor tissue. By modifying the tumor-targeting component, such as an antibody or nanobody against a chosen antigen, the same enzyme-probe pair could, in theory, be adapted to target other cancer types.
Looking even further ahead, this research opens doors to highly targeted drug delivery, where cancer-fighting drugs could be precisely delivered to affected sites, avoiding healthy tissues. As Kojima emphasizes, while the potential is exciting, it's still early days, and much work is needed before human trials can be considered.
This research showcases the potential for groundbreaking advancements in cancer detection and treatment, offering hope for improved surgical outcomes and potentially saving countless lives.
